168 related articles for article (PubMed ID: 22355307)
1. Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.
Lataillade M; Chiarella J; Yang R; DeGrosky M; Uy J; Seekins D; Simen B; St John E; Moreno E; Kozal M
PLoS One; 2012; 7(2):e30118. PubMed ID: 22355307
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of minor drug-resistant viral variants in patients experiencing virological failure (VF) on a first-line regimen in Fujian Province by high-throughput sequencing.
Deng Y; Wu S; Qiu L; Yan Y
Ann Palliat Med; 2021 Jul; 10(7):7775-7785. PubMed ID: 34353064
[TBL] [Abstract][Full Text] [Related]
3. No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
Perrier M; Visseaux B; Landman R; Joly V; Todesco E; Yazdanpanah Y; Calvez V; Marcelin AG; Descamps D; Charpentier C
J Antimicrob Chemother; 2018 Jan; 73(1):173-176. PubMed ID: 29077926
[TBL] [Abstract][Full Text] [Related]
4. Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
Ross LL; Weinberg WG; DeJesus E; Fischl MA; Horton JH; Pappa KA; Lancaster CT; Pakes GE; Smith KY
AIDS Res Hum Retroviruses; 2010 Apr; 26(4):407-17. PubMed ID: 20380480
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
Gilliam BL; Chan-Tack KM; Qaqish RB; Rode RA; Fantry LE; Redfield RR
AIDS Patient Care STDS; 2006 Nov; 20(11):745-59. PubMed ID: 17134349
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure.
Vandenhende MA; Bellecave P; Recordon-Pinson P; Reigadas S; Bidet Y; Bruyand M; Bonnet F; Lazaro E; Neau D; Fleury H; Dabis F; Morlat P; Masquelier B
PLoS One; 2014; 9(1):e86771. PubMed ID: 24475178
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study.
Lataillade M; Chiarella J; Yang R; Schnittman S; Wirtz V; Uy J; Seekins D; Krystal M; Mancini M; McGrath D; Simen B; Egholm M; Kozal M
PLoS One; 2010 Jun; 5(6):e10952. PubMed ID: 20532178
[TBL] [Abstract][Full Text] [Related]
8. From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
Namakoola I; Kasamba I; Mayanja BN; Kazooba P; Lutaakome J; Lyagoba F; Kapaata AA; Kaleebu P; Munderi P;
BMC Res Notes; 2016 Dec; 9(1):515. PubMed ID: 28010730
[TBL] [Abstract][Full Text] [Related]
9. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
10. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
[TBL] [Abstract][Full Text] [Related]
12. Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
Lambert-Niclot S; Grude M; Chaix ML; Charpentier C; Reigadas S; Le Guillou-Guillemette H; Rodallec A; Amiel C; Maillard A; Dufayard J; Mourez T; Mirand A; Guinard J; Montes B; Vallet S; Marcelin AG; Descamps D; Flandre P; Delaugerre C; Morand-Joubert L;
J Antimicrob Chemother; 2018 Aug; 73(8):2147-2151. PubMed ID: 29718247
[TBL] [Abstract][Full Text] [Related]
13. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
[TBL] [Abstract][Full Text] [Related]
14. HIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, China.
Chen X; Zou X; He J; Zheng J; Chiarella J; Kozal MJ
PLoS One; 2016; 11(2):e0149215. PubMed ID: 26895182
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
Kozal MJ; Chiarella J; St John EP; Moreno EA; Simen BB; Arnold TE; Lataillade M
Antivir Ther; 2011; 16(6):925-9. PubMed ID: 21900725
[TBL] [Abstract][Full Text] [Related]
16. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
17. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
[TBL] [Abstract][Full Text] [Related]
18. Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.
Hsieh SM; Chang SY; Hung CC; Sheng WH; Chen MY; Chang SC
BMC Infect Dis; 2009 Sep; 9():154. PubMed ID: 19751502
[TBL] [Abstract][Full Text] [Related]
19. Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
Moyle GJ; Hardy H; Farajallah A; DeGrosky M; McGrath D
Clin Drug Investig; 2014 Apr; 34(4):287-96. PubMed ID: 24557728
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
Rhee SY; Jordan MR; Raizes E; Chua A; Parkin N; Kantor R; Van Zyl GU; Mukui I; Hosseinipour MC; Frenkel LM; Ndembi N; Hamers RL; Rinke de Wit TF; Wallis CL; Gupta RK; Fokam J; Zeh C; Schapiro JM; Carmona S; Katzenstein D; Tang M; Aghokeng AF; De Oliveira T; Wensing AM; Gallant JE; Wainberg MA; Richman DD; Fitzgibbon JE; Schito M; Bertagnolio S; Yang C; Shafer RW
PLoS One; 2015; 10(12):e0145772. PubMed ID: 26717411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
